Pfizer

News

scientifically visualization of a coronavirus spike protein

Pfizer, Moderna are prepping new vaccines for Omicron

With evidence growing that the current crop of COVID-19 vaccines are less protective against infection with Omicron, both Pfizer and Moderna have announced plans to develop new versions of

R&D

Beyond the pandemic: the potential of mRNA technology

The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease.

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AstraZeneca goes bigger in amyloidosis with Neurimmune deal

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of mo

News

Look out GSK, Pfizer and BioNTech are coming for Shingrix

GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion.

News

Talking vaccines: Industry’s role in protecting the Gavi generation

FDA clears Pfizer, BioNTech COVID booster for younger teens

The FDA has authorised the first COVID-19 booster vaccine for teenagers in the 12 to 15 age group, giving the okay for wider use of Pfizer and BioNTech's Comirnaty shot as it tries to keep

News

Leo puts target on Dupixent in US as FDA clears tralokinumab

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma's rival antibody tralokinumab.

Pfizer, Moderna are prepping new vaccines for Omicron

Beyond the pandemic: the potential of mRNA technology

AstraZeneca goes bigger in amyloidosis with Neurimmune deal

Look out GSK, Pfizer and BioNTech are coming for Shingrix

FDA clears Pfizer, BioNTech COVID booster for younger teens

Leo puts target on Dupixent in US as FDA clears tralokinumab

Andexxa reaches the end of the line in the US

How to meet your physicians where they are online

Pfizer

Editor's Picks